Sangamo Therapeutics (SGMO)

• Market cap: $121M
• 1 day: -1.60%
• 5 days: -8.29%
• 1 month: -5.20%
• 3 months: -31.52%
• 6 months: -54.44%
• Year to date: -56.46%
• 1 year: 12.23%
• 5 years: -95.20%
• 10 years: -95.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Employees: 183

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 33

4% less call options, than puts

Call options by funds: $1.77M | Put options by funds: $1.84M

5% less funds holding

Funds holding: 128 [Q4 2024] → 122 (-6) [Q1 2025]

6.12% less ownership

Funds ownership: 29.51% [Q4 2024] → 23.39% (-6.12%) [Q1 2025]

18% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 28

45% less capital invested

Capital invested by funds: $62.9M [Q4 2024] → $34.5M (-$28.4M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 916% upside
• Avg. target: $7.50 1,424% upside
• High target: $10 1,933% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio	1,933% upside $10	Buy Reiterated	24 Jun 2025
Barclays Gena Wang	916% upside $5	Overweight Maintained	14 May 2025